Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EDNRB | P24530 | 20/20 | 0.79 |
| ▸ | EDNRA | P25101 | 20/20 | 0.79 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.56 |
| ▸ | TSPO | P30536 | 1/20 | 0.56 |
| ▸ | DRD3 | P35462 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5632255 | 0.90 | EDNRA (0.75) | EDNRBEDNRASLC6A2TSPODRD3 | |
| SCHEMBL9891392 | 0.88 | EDNRA (1.00) | EDNRBEDNRASLC6A2TSPODRD3 | |
| SCHEMBL1003217 | 0.86 | EDNRB (0.60) | EDNRBEDNRASLC6A2TSPODRD3 | |
| SCHEMBL14380766 | 0.84 | EDNRB (0.84) | EDNRBEDNRASLC6A2TSPODRD3 | |
| SCHEMBL12973800 | 0.83 | EDNRA (0.78) | EDNRBEDNRASLC6A2TSPODRD3 | |
| SCHEMBL9891390 | 0.83 | EDNRA (0.77) | EDNRBEDNRASLC6A2TSPODRD3 | |
| SCHEMBL5632084 | 0.82 | EDNRA (1.00) | EDNRBEDNRASLC6A2TSPODRD3 | |
| SCHEMBL14380566 | 0.82 | EDNRA (0.64) | EDNRBEDNRASLC6A2TSPODRD3 | |
| SCHEMBL31442543 | 0.82 | EDNRA (0.64) | EDNRBEDNRASLC6A2TSPODRD3 | |
| SCHEMBL31442652 | 0.80 | EDNRA (0.76) | EDNRBEDNRASLC6A2TSPODRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8324232-B2 | 4-pyrimidinesulfamide derivative | ACTELION PHARMACEUTICALS LTD. (CH) | 2012-12-04 | — | — | US | disclosed |
| US-8324232-B2 | 4-pyrimidinesulfamide derivative | ACTELION PHARMACEUTICALS LTD. (CH) | 2012-12-04 | — | — | US | disclosed |
| EP-2190837-B1 | 4-PYRIMIDINESULFAMIDE DERIVATIVE | ACTELION PHARMACEUTICALS LTD (CH) | 2012-08-15 | — | — | EP | disclosed |
| US-20120142716-A1 | 4-PYRIMIDINESULFAMIDE DERIVATIVE | IDORSIA PHARMACEUTICALS LTD (CH) | 2012-06-07 | — | — | US | disclosed |
| US-20120142716-A1 | 4-PYRIMIDINESULFAMIDE DERIVATIVE | IDORSIA PHARMACEUTICALS LTD (CH) | 2012-06-07 | — | — | US | disclosed |
| WO-2009024906-A1 | 4-PYRIMIDINESULFAMIDE DERIVATIVE | ACTELION PHARMACEUTICALS LTD (CH) | 2009-02-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120142716-A1 | 4-PYRIMIDINESULFAMIDE DERIVATIVE | EDNRB, EDNRA, TBXA2R | EDNRB 1/4885EDNRA 2/4885SLC6A2 834/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.